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Aim: To produce marine-origin nanoparticles (NPs) aiming to develop more effective and tolerated ther-
apies for breast cancer. Materials & methods: NPs based in two marine-origin polymers (fucoidan and
chitosan) were prepared by polyelectrolyte complexation, for the delivery of an antitumor drug model
(gemcitabine [Gem]). Results: Final formulation resulted in stable NPs around 115–140 nm in size and
with a polydispersity index less than 0.2. Gem was encapsulated at a maximum entrapment efficiency of
35–42%. Drug-release studies demonstrated that around 84% of Gem is released within 4 h. Cytotoxicity
results of Gem-loaded NPs showed increased toxicity (around 25%) when compared with free Gem. Con-
clusion: The drug-loaded NPs present increased toxicity over human breast cancer cells without increasing
toxic effects over endothelial cells.
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Cancer is one of the leading causes of death worldwide and is characterized by the uncontrolled and fast growth
of cells. In 2012, there were around 14 million new cases of cancer and around 8 million resulted in death. By
2035, it is expected to be around 24 million new cases per year [1]. Breast cancer is the most common cancer
in females and the second deadliest [2]. Surgery, radiation and systemic therapies (chemotherapy, hormonal and
target) are some of the current breast cancer treatment modalities available, depending on the extent and type of
cancer [3]. Some of these treatments may present some limitations since, besides affecting the tumor, they also affect
the surrounding healthy environment, and may present some side effects [3,4]. For these reasons, the use of natural
substances is an interesting alternative due to their low toxicity and biological and chemical similarities to native
tissue compositions.
Among natural substances, marine organisms are valuable sources of materials with intriguing properties and
characteristics [5]. Fucoidan (Fu) is a naturally derived sulfated polysaccharide extracted from brown seaweed
and has been extensively investigated because of its various biological properties such as anticoagulant, antiviral,
antiangiogenic, anti-inflammatory, immunomodulating and, most recently, antitumor behavior [6,7]. Looking
specifically at its antitumoral behavior, we recently reported that different Fu extracts present different biological
responses over human breast cancer and noncancer cell lines with chemical structure apparently playing an important
role [8]. Some Fu extracts presented the desired antitumoral behavior, whereas other presented toxicity for both
cancer and noncancer cells or where nontoxic for both types of cells, depending on their chemical features.
In this work, we propose the use of nontoxic Fu to develop a natural marine-origin drug delivery system (DDS)
for the release of anticancer drugs. Indeed, Fu have been included in nanosystems for diagnostic, drug delivery and
regenerative medicine [9,10] and have been combined with chitosan (CH), a marine-derived polycation, to prepare
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nanoparticles (NPs) by polyelectrolyte complexation for the delivery of growth factor drugs and other biological
compounds [10–13].
NPs have been developed as DDS for the delivery of drugs or biomolecules. NPs-based DDS presents attractive
properties since they can pass through the smallest capillary vessels and penetrate cells/tissue gaps to arrive at the
target site [14,15]. They may also improve macromolecule stability, protecting them from enzymatic degradation
and controling their release profile. However, they may present some limitations like drug loss during circulation
and limited drug-loading capacity.
Gemcitabine (Gem), an antitumor drug, has been applied in the treatment of different cancers such as lung,
ovary and pancreatic [16–18]. It has been also used in the treatment of breast cancer, as a single therapy or in
combination with other chemotherapeutic agents [19,20]. Gem is a nucleoside analog that inhibits DNA synthesis,
by its incorporation into DNA, followed by inhibition of cell proliferation. Gem presents a short biological half-
life, being rapidly metabolized. This limits its biological effectiveness, since higher doses are required to reach a
therapeutic concentration, increasing the risk of side effects [21,22]. In this sense, there is the unmet therapeutic
need to try to enhance Gem biological response by incorporating it into a DDS, which has been previously
reported [23,24].
To the best of our knowledge, there are no reports in the literature regarding the development of Fu/CH
NPs for the delivery of Gem. In this sense, we propose the combination of Fu (negatively charged) with CH
by polyelectrolyte complexation to produce NPs for controlled release of Gem as potential breast cancer therapy.
Regarding NP production, there are different parameters that need to be optimized such as polymers concentration
and ratio, polymeric solution pH and ionic strength. Therefore, these different parameters were tested and combined
to obtain the NPs with smaller size and polydispersity index (PDI). NPs stability is another important aspect that
needed to be evaluated. Keeping in mind the tumor microenvironment, NPs toxicity was evaluated over cancer
and noncancer cells. The release profile of Gem was analyzed and loaded-NPs tested over endothelial and breast
cancer cells as an in vitro assessment of antitumor efficiency through cytotoxicity.
Experimental section
Materials
Fu from Fucus vesiculosus (molecular weight [MW] by gel permeation chromatography [GPC] 45–75 kDa) was
purchased from Marinova (batch number: DPFVF2015505), whereas CH 95/20 (MW by GPC 40–150 kDa)
was purchased from Heppe Medical Chitosan GmbH (batch number: 212-261115-04, Halle, Germany). 1-
[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were
both purchased from Sigma-Aldrich (MO, USA). Centrifugal concentrators Vivaspin 20 300 KD (Sartorius;
Stonehouse, UK) were purchased from Fisher Scientific. 2′-Deoxy-2′,2′-difluorocytidine (Gem – C9H11F2N3O4)
was purchased from Carbosynth (Berkshire, UK). Human umbilical vein endothelial cells (EA.hy926) and breast
cancer cells (MDA-MB-231) were both purchased from ATCC (VA, USA).
Methods
Preparation of NPs
Marine-origin polymeric NPs were prepared by polyelectrolyte complexation. Optimization was performed to study
the effect of different parameters over size and PDI. From the results obtained, for each parameter, we chose the
production condition that combined the smaller size and PDI values. Different parameters were evaluated, such
as concentration of both polymers (ranging from 0.25 to 1 mg/ml); the ratio of polymers solution (CH:Fu – 1:2,
1:1, 2:1); CH and Fu solutions pH; ionic strength (ultrapure water [UPW], osmotized water and 0.9% NaCl)
and cross-linking agent concentrations: 600/240, 300/120 and 150/60 mM (EDC/NHS). Each parameter was
evaluated separately while all the others were kept constant.
After all the optimization steps, NP parameters were maintained for all further assays. Briefly, CH was dissolved
in 1% v/v acetic acid solution at 0.5 mg/ml concentration, whereas the polyanion (Fu) was prepared in UPW to
reach a final concentration of 0.5 mg/ml. CH and Fu solutions were adjusted with 1 M HCl and 1 M NaOH,
depending on the desired pH. CH solution was adjusted to pH 5, whereas Fu solution was measured and the
pH adjusted if its values were not as expected (pH 9). 3 nl of Fu solution (0.5 mg/ml) was added, using a
precision syringe pump, to 3 ml of CH solution (0.5 mg/ml) leading to a final theoretical ratio (w/w) of 1:1 and a
spontaneous formation of NPs occured. Right after NP production, 300 mM EDC + 120 mM NHS were added
to the NP solution. NPs were stirred for 2 h at 600 rpm. After that, NPs were collected using 300 kDa vivaspin
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filters for 15 min at 4000 rpm. NPs were washed twice with UPW. Glucose was added in all centrifugation steps
to avoid NP aggregation. Finally, NPs were filtered with 0.22 μm filters.
Characterization of NPs
Dynamic light scattering
NP size and PDI were determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern
Instruments, Malvern, UK). Samples were diluted in UPW and the size analysis lasted 180 s and performed at
25◦C, in triplicate. The zeta potential measurements were performed by a dip cell in automatic mode.
NP tracking analysis
NP tracking analysis (NTA) experiments were performed using a NanoSight NS500 instrument (Malvern Panalyt-
ical, Salisbury, UK). This system includes a charge-coupled device camera that allows visualization and tracking of
Brownian motion of laser-illuminated particles in suspension. Video images were analyzed using NTA analytical
software version 2.3. The measurements were made at room temperature and each video sequence was captured
over 60 s.
Scanning electron microscopy & scanning transmission electron microscopy
Measurement of particles’ size and morphology observation were obtained using SEM (Scanning electron mi-
croscopy; Auriga, Carl Zeiss). A drop of NPs solution was placed in the stub for SEM analysis and left to dry
overnight. They were then vacuum-coated with a gold–platinum mixture. Scanning transmission electron mi-
croscopy (STEM) analysis was also performed with the same equipment.
NPs physiological & storage stability
To mimic and assess the stability of NPs at physiological conditions, the NPs were diluted in 0.9% NaCl and kept
at 37◦C. The size and PDI of NPs were measured by DLS every day, until day 7.
To evaluate NPs storage stability after production, NPs were diluted in UPW and kept at 4◦C. NPs size and PDI
were measured by DLS every week for up to 2 months.
NPs cytotoxicity
Cell culture & cell viability
The cytotoxicity of the optimized NPs was evaluated over human umbilical vein endothelial (EA.hy926, cell line)
and breast cancer (MDA-MB-231, cell line) cells. Increasing concentration of NPs were used until toxic effects were
observed. The CellTiter 96 AQueous One Solution cell proliferation assay (Promega; WI, USA) was performed at
24, 48 and 72 h. At these time points, the culture medium was removed and the testing samples were rinsed with
sterile phosphate-buffered saline (PBS). A mixture of culture medium (without Fetal Bovine Serum and phenol
red) and MTS reagent (5:1 ratio) was added to each well and left to incubate for 3 h, at 37◦C, in a humidified
5% CO2 atmosphere. Thereafter, the absorbance of the MTS reaction medium from each sample was read in
triplicate at 490 nm in a microplate reader (Synergy HT, Bio-TEK). All experiments were performed in triplicate.
This experiment was repeated with Gem-loaded NPs (NPs Gem), the amount of free Gem being the same as the
amount loaded into the developed NPs.
Drug encapsulation & release studies
Drug entrapment efficiency
Gem concentrations, ranging from 0.2 to 3.2 mg/ml, were encapsulated into the NPs’ optimized formulation.
Gem was added to CH solution and NPs were produced as described in the section titled Preparation of NPs,
maintaining the same production conditions (CH:Fu:Gem ratio 1:1:0.3).
Entrapment efficiency (EE) was calculated by measuring the initial concentration and nonencapsulated Gem,
according to the following formula:
%
( )
EE
Initial concentration non entrapped drug
initial conc
= - -  
 entration
´100
The samples were analyzed by UV spectroscopy (Shimadzu) at the maximum absorbance of 268 nm. All the
experiments were performed in triplicate.
future science group 10.2217/nnm-2018-0004
Research Article Oliveira, Neves, Reis, Martins & Silva
Gem-release studies
The release kinetics of Gem was measured by placing 1.5 ml of NPs Gem into dialysis membranes, and this system
into 50 ml of 0.9% NaCl at 37◦C under 60 rpm stirring. At predetermined time periods (0, 5, 15, 30, 45 min;
1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48 and 72 h), an aliquot of 2 ml of the release solution was taken and immediately
measured at the previously defined absorbance. The experiments were performed in triplicate.
Statistical analysis
Statistical analysis was performed using Graph Pad Prism Software. Differences between the different conditions
of the cellular assays were analyzed using nonparametric test (Kruskal–Wallis test), and p < 0.05 was considered
significant. Data are presented as mean ± standard deviations.
Results
Optimization of NPs production parameters
To produce marine-origin polymeric NPs with constant sizes, several processing parameters were tested, namely
polymers concentration and ratios, pH of the solution, ionic strength and influence of the cross-linker. Experimental
results point out that a decrease in polymers concentration leads to the formation of smaller NPs (Figure 1A).
With the same trend, the PDI tends to decrease for concentrations down to 0.5 mg/ml. However, for the
lowest concentration, the PDI slightly increased indicating that at this polymers concentration the NPs are less
homogenous. In this sense, and by the combination of these two important properties, the working concentration
was set as 0.5 mg/ml for both CH and Fu. When Fu is in excess (CH:Fu ratio 1:2) in the final formulation, the
NPs present a size around 500 nm and are highly polydispersive (PDI > 0.3; Figure 1B). For the 2:1 ratio, the NPs
present a higher PDI than 1:1. Therefore, this last ratio was used for all further experiments. The influence of pH
solution was evaluated for each polymer separately, maintaining the pH of the other polymer solution (Figure 1C
& D). For the CH solution, pH 5 was chosen, whereas for Fu the testing condition that presented smaller size
and PDI values was the one with pH 9 (pH of Fu solution). Ionic strength was also evaluated by dissolving the
polymers in different solvents with increasing ionic strength: UPW, osmotized water and 0.9% NaCl. UPW was
the condition where the NPs presented the lower PDI and size values (Figure 1E). Taking together, the optimal
production parameters were set as: 0.5 mg/ml of both CH and Fu, 1:1 ratio, pH 5 (CH) and pH 9 (Fu) and UPW
as the polymers solvent. After setting these parameters, the concentration of a cross-linking agent was evaluated.
Different concentrations of EDC/NHS were tested, being the 300 mM of EDC and 120 mM of NHS, the
condition that presented the best outcomes in terms of size and PDI (Figure 1F).
NPs characterization
NPs stability
After optimizing all the production parameters, two different conditions were chosen to continue the charac-
terization of the NPs: one without cross-linking (no EDC/NHS) and the other cross-linked with EDC/NHS
(300 mM EDC + 120 mMNHS). These two conditions were used to perform stability assays, both at physiologi-
cal conditions (37◦C, 0.9% NaCl; Figure 2A) and for storage conditions (4◦C, UPW; Figure 2B). At physiological
conditions, both size and PDI increase along the 7 days of the study, presenting values for PDI above 0.3 from day
4 on, concerning noncross-linked NPs. The size of cross-linked NPs was stable along the 7 days, whereas the PDI
presents some slightly variations in some time points, these values being below 0.2. For the storage condition, both
types of NPs present no significant variations in terms of size and PDI for up to 2 months.
NP properties
Based on stability results, cross-linked NPs were further characterized. NPs present a size of 140 nm, a PDI = 0.172
and a zeta potential of 29 mV by DLS (Table 1). NPs were also evaluated by NTA, presenting a size around 116 nm
and a final concentration of 7.81 × 1010/ml.
Nanoparticle morphology and size in dry state were also observed by SEM and STEM (Figure 3A & B). NPs
presented a round shape and a size smaller than 100 nm in both microscopic analyses.
NP cytotoxicity
After optimizing all the parameters, the cytotoxicity of the developed NPs was evaluated over human endothelial
(Figure 4A) and breast cancer (Figure 4B) cells. Different concentrations of NPs were tested and, for concentrations
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Figure 1. Nanoparticles’ size and polydispersity index at different production parameters. (A & B) Evaluation of CH and Fu
concentration and ratio (CH + Fu), respectively. (C & D) Evaluation of the influence of CH and Fu solutions’ pH, respectively. (E) Influence
of ionic strength and (F) Evaluation of different cross-linker (EDC/NHS) concentrations.
CH: Chitosan; EDC: 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride; Fu: Fucoidan; PDI: Polydispersity index; NHS:
N-hydroxysuccinimide.
above 8 × 109 NPs/ml they start to be toxic for both cell types, despite some significant differences in previous
concentrations and time points. By SEM analysis, it was possible to observe the presence of the NPs at the surface
of both cell types.
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Figure 2. Nanoparticle stability. Size and polydispersity index of NPs at physiological (37◦C and 0.9% NaCl; A & B)
and storage conditions (4◦C and UPW; C & D). (A & C) Regard size and (B & D) Regard PDI.
EDC: 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride; NHS: N-hydroxysuccinimide; PDI: Polydispersity
index; UPW: Ultrapure water.
Table 1. Nanoparticles characterization by dynamic light scattering and nanoparticle tracking analysis.
Technique Property Value
DLS Size (nm) 141 ± 17
PDI 0.172 ± 0.020
Zeta potential (mV) 28.9 ± 3.5
NTA Size (nm) 116 ± 17
Concentration (particles/ml) 7.8 × 1010 ± 1.2 × 1010
DLS: Dynamic light scattering; NTA: Nanoparticle tracking analysis; PDI: Polydispersity index.
Drug entrapment efficiency & release studies
Gem entrapment efficiency
The drug entrapment efficiency was assessed by testing different Gem concentrations. Concentrations of 0.8 and
1.6 mg/ml present similar values and a maximum EE between 36 and 42%, respectively. At higher concentrations,
the system saturates and the EE decreases to values around 30%.
In this sense, 0.8 mg/ml was the chosen concentration to evaluate the Gem-release profile, as well as the cytotoxic
effects of NPs Gem over human endothelial and breast cancer cells. NPs Gem presented a size around 134 nm and
a PDI of 0.186 (Figure 5B), similar to the values observed for the nonloaded NPs (Table 1).
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100 nm
Figure 3. Nanoparticles morphology. Observation by scanning electron microscopy (SEM; A) and scanning
transmission electron microscopy (STEM; B).
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Figure 4. Cytotoxicity of developed NPs. Influence of NPs concentrations over human endothelial (A) and breast
cancer (B) cells at different time points (1, 2 and 3 days). Data were considered statistically significant at p < 0.05.
*Indicates significant differences compared with CTR; Compared with 4 × 108; §Compared with 8 × 108; +Compared
with 2 × 109; &Compared with 4 × 109 and %Compared with 8 × 109. SEM observation of control and 4 × 109 NPs/ml
culture conditions at day 3.
CTR: Control; NP: Nanoparticle; SEM: Scanning electron microscopy.
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Figure 5. Gem-loaded NPs. Entrapment efficiency (A) and size distribution representation (B).
Gem: Gemcitabine; NP: Nanoparticle.
Gem-release profile
The release ofGem frommarine-origin polymericNPswas evaluated at 37◦Cand 0.9%NaCl tomimic physiological
conditions. Figure 6 shows that the developed system releases around 84% of the drug in a sustained way during
4 h, then maintaining a steady-state profile for up to 72 h.
Cytotoxic effects of drug-loaded NPs over cancer & noncancer cells
NPs at 4 × 109 NPs/ml do not present statistical significant differences when compared with the control condition
for both endothelial and breast cancer cells, in all time points evaluated (Figure 7), confirming the results already
reported in Figure 4. However, NPs Gem are cytotoxic for breast cancer cells since the first day, but being also
cytotoxic at days 2 and 3 for endothelial cells. Free Gem also presents cytotoxicity to endothelial cells with similar
values to the ones observed with NPs Gem. Concerning breast cancer cells, NPs Gem present increased toxicity at
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Figure 6. Gemcitabine-release profile from marine-origin polymeric nanoparticles (0.9% NaCl, 37◦C, 60 rpm).
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Figure 7. Cytotoxicity of developed Gem-loaded NPs. Influence over human endothelial (A) and breast cancer (B)
cells at different time points (1, 2 and 3 days). Data were considered statistically significant at p < 0.05. *Indicates
significant differences compared with CTR; #Compared with NPs; &Compared with NPs Gem.
CTR: Control; NP: Nanoparticle; NP Gem: Gemcitabine-loaded NP.
future science group 10.2217/nnm-2018-0004
Research Article Oliveira, Neves, Reis, Martins & Silva
day 2 (15%) and at day 3 (25%) when comparing with free Gem. Furthermore, NP Gem presents higher toxicity
over breast cancer than endothelial cells at day 3 (17%).
Discussion
Polyelectrolyte complexation has been widely reported due to its cost–effectiveness and easy production of NPs.
It takes advantage of the interactions between two oppositely charged polymers and a spontaneous formation of
the NPs occurs [25]. There are different parameters described to affect NPs size and PDI, namely the polymer
concentration and ratio, polymer solution pH and ionic strength [26,27]. Our results showed that by decreasing
polymers concentration, it was possible to obtain similar NPs.
However, higher PDI values are observed for both the high and low concentrations, showing obtainance of NPs
with a nonhomogenous size distribution. Thus, it seems that at higher concentrations there would be high entropy
and at lower concentrations reduced interactions between oppositely charged polymers. The influence of polymers
ratio was also evaluated over NPs’ size and PDI. When higher amounts of Fu are present (CH:Fu ratio 1:2), the NPs
present an increased size and PDI, showing that probably there is the formation of polymeric aggregates instead
of NPs. Indeed, the amino groups of CH have a pKa of approximately 6.5, which leads to a protonation in acidic
conditions. In solutions with pH>6.5, most amino groups would be deprotonated and CH tends to precipitate [28].
Being deprotonated, the amine groups will be less available to form a complex with Fu, resulting in a less controlled
process, with the participation of other types of interactions gaining relevance, which will result in higher variability
and consecutively high values of size and PDI, outside the range to be considered as NPs. CH at acidic pHs
present protonated amines being as these chemical groups are more prone to form polyelectrolyte complexes with
a negatively charged polymer (Fu), with ionic attractive interactions ruling the process, leading to the formation
of the desired NPs. Despite similar size values for the three other pHs, pH 5 was the one that presented more
homogeneous NPs’ size. Fu solution pH seems not to influence the development of NPs size, although a low PDI
value is observed when the pH is not adjusted (pH 9; Figure 1C & D). Ionic strength was analyzed by dissolving
the polymers in different solvents, UPW being the one that presents the better outcomes in terms of size and PDI.
As expected, 0.9% NaCl tends to form bigger and nonhomogenous NPs due to the presence of higher amounts of
ions, which would have a charge shielding effect over the protonated groups in polyelectrolytes and thus decreasing
the relevance of ionic interactions in the assembly process. Fu/CH NPs may become unstable at physiological
conditions due to the deprotonation of CH amine groups. Trying to enhance NPs stability, a cross-linking agent
was tested: EDC/NHS. EDC is often used to cross-link amines (NH2) to carboxylate groups, whose activity is
enhanced by NHS, through activation of the carboxylate group [29]. In the present case, the rationale is to cross-link
the amine groups of CH with the carboxylic group of the uronic acids that are present in Fu structure [8]. Different
concentrations of EDC/NHS were evaluated and the 300 mM EDC + 120 mMNHS presented the smaller PDI.
Despite 150 mM EDC + 60 mM NHS present similar results, these concentrations presented higher PDI, reason
why a higher concentration was chosen to continue the study. Higher concentrations (600 mM EDC + 240 mM
NHS) seem to start precipitating and affecting NPs’ size, increasing it to around 300 nm. NPs final formulation
was set as: 0.5 mg/ml polymers concentration, 1:1 ratio, pH 5 (CH) and pH 9 (Fu) and UPW as the polymers
solvent.
After this optimization process and setting all the parameters, two conditions were chosen to conduct the stability
assays: one without cross-linking and the other cross-linked. NPs stability at physiological and storage conditions
was assessed. Physiological conditions were mimetized by diluting the produced NPs in 0.9% NaCl, which have
an osmolarity similar to circulating plasma 285–295 mOsm/l [30]. Both NPs increase their size to around 200 nm,
when in contact with this isotonic solution, due to an increase in the ionic strength with associated charge shielding
but also higher water uptake (Donnan effect) [31]. Cross-linked NPs present a quite stable profile along the 7 days,
whereas from day 3 on, the noncross-linked NPs start to increase their size, indicating that they probably start to
disintegrate at physiological osmolarity. We proceed the characterization of cross-linked NPs that present a size
around 140/115 nm (DLS/NTA), a PDI of 0.172, which indicates that these NPs are quite homogeneous and a
zeta potential of +29 mV indicating that CH is at the surface of NPs. By NTA, the NPs presented a smaller size
due to the fact that NTA is a more precise technique than DLS [32]. By SEM and STEM observation, we were able
to confirm the round morphology of the NPs, with a size smaller than 100 nm. The difference between DLS/NTA
measurements and SEM/STEM is due to the fact that in the first characterization, NPs are measured in wet state,
whereas for SEM/STEM, NPs are analyzed in a dry state.
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After all the optimization steps, the cytotoxicity of the developed marine-origin polymeric NPs was evaluated
over human endothelial and breast cancer cells at different concentrations. NPs start to become more toxic to both
cell types at the highest concentrations (8 × 109 and 16 × 109 NPs/ml) tested. From SEM observation, we were
able to observe NPs at the surface of both cell types. From these results, 4 × 109 NPs/ml concentration (nontoxic
concentration) was selected to conduct the further experiments.
Breast cancer is sensitive to several cytotoxic drugs that may be used as single or combined therapies. In the
past years, new cytotoxic agents have been developed and approved to be used in cancer treatments. Gem has
shown antitumoral activity and good toxicity profiles to be used as single-agent therapy for advanced breast cancer.
One of the drawbacks of using Gem by intravenous or oral administration is related with its rapid inactivation by
enzymatic delamination, low bioavailability and short half-life. These problems require an increase in dosage that
may lead to unwanted side effects [19–22]. The use of NPs may overcome some of these limitations since they will be
able to protect the drug from enzymatic degradation, diminishing the above-mentioned efficiency problems [33].
The loading of Gem on the marine-origin polymeric NPs was evaluated by testing different Gem concentrations.
In Figure 5A, it is possible to observe that, by increasing the concentration of the drug, there is an increase in the
EE until it reaches a maximum concentration of 1.6 mg/ml (EE = 42%). At 3.2 mg/ml, the system saturates and
the EE decreases to around 30%. NPs Gem were characterized in terms of size and PDI, showing no significant
differences. The release profile was assessed at 37◦C and 0.9% NaCl to mimic physiological conditions. From the
stability studies, it was observed that the size of the NPs increased, due to the ionic strength of the solution that
weakens the electrostatic interactions, leading to the release of Gem from the NPs [10]. Around 84% of Gem was
released in the first 4 h in a sustained way, until reaching a steady state.
To assess the antitumoral activity of the developed DDS, it is important to have in mind the tumor microen-
vironment that comprises not only cancer cells but also noncancer cells (e.g., endothelial, fibroblasts). Indeed, as
NPs Gem are intended to be injected intravenously, the first barrier they will face is the blood vessels wall and thus
endothelial cells. Different Fu-based NPs have been developed as anticancer strategies. As example, Fu–cistaplin
NPs have been developed and evaluated for colon cancer [34], whereas Fu encapsulated into liposomes showed an-
ticancer activity against osteosarcoma [35]. In another attempt, doxorubicin was incorporated into a protamine/Fu
system and these loaded NPs improved inhibitory effects against a breast cancer cell line [36]. However, as far as we
know there are no studies in the literature that report the use of Fu to develop NPs for the delivery of Gem. On
the other hand, CH-based NPs have been studied for the delivery of antitumoral agents, namely for the delivery
of Gem. For example, the loading of Gem into CH magnetic NPs increased Gem efficacy when compared with
free Gem [37]. In other study, CH-based NPs were prepared by layer-by-layer technique for the incorporation of
Gem and platinum aiming at lung cancer treatments [38]. Other studies reported the use of CH-based NPs for the
delivery of other antitumor drugs: PEG-layered CHNPs enhanced the efficacy of ormeloxifene in breast cancer [39]
and platinum–gold NPs with CH and doxorubicin presented cell-specific cytotoxicity [40].
In this sense, the combination of these two marine-origin polymers to develop NPs for the delivery of Gem is a
novel process with potential positive outcome. We evaluated the Gem loaded-NPs toxicity over human endothelial
and breast cancer cell lines. Regarding endothelial cells, both NPs Gem and free Gem present similar cytotoxicity
values. However, concerning breast cancer cells, NPs Gem increased toxic effects of around 15 and 25% at days 2
and 3, respectively, when compared with free Gem. At day 3, when comparing breast cancer and endothelial cells,
it was observed an increased cytotoxicity of around 17% over breast cancer cells. The increased cytotoxicity of the
NPs Gem when compared with free Gem may be attributed to the cellular trafficking pathway, suggesting a more
effective uptake of the drug by breast cancer cells. The encapsulation of cisplatin into CH lipid NPs was reported,
demonstrating increased apoptosis in cancer cells when compared with free cisplatin [41]. A recent paper reported
that CH NPs loaded with curcumin reduced the drug uptake in normal cells, while the same was internalized
into cancer cells [42]. Another study reported the internalization of CH-coated NPs loaded with doxorubicin into
breast cancer cells cytoplasm and nucleus. The authors stated that the uptake of these NPs may be attributed to the
positive charge of their surface. That positively charged CH NPs can have charge-based interaction with the cell
membrane and may enter cells either by direct penetration or by endocytosis [43]. Thus, although not presenting a
protective effect against the toxicity over endothelial cells, the Fu/CH NPs exhibit a synergistic effect with Gem
resulting in a higher toxicity over breast cancer cells. Moreover, these results confirm that, by encapsulating Gem
into an NP, the drug is protected from enzymatic degradation, increasing its half-life and biological response.
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Conclusion
Marine-origin polymeric NPs were successfully produced by polyelectrolyte complexation, presenting increased
stability at physiological conditions when cross-linked with EDC/NHS. Gem was encapsulated in the developed
NP system. This DDS increased toxicity over human breast cancer cells, when compared with free Gem, without
increasing their toxic effect over endothelial cells. Taken together, the herein-developed DDS is an interesting
strategy to be further explored on breast cancer therapies.
Summary points
Nanoparticle production & characterization
• Nanoparticles (NPs) were successfully produced by polyelectrolyte complexation, presenting a size around
115–140 nm.
• NPs present a polydispersity index less than 0.2, demonstrating NPs’ size homogeneity.
• Cross-linked NPs presented increased stability at physiological conditions than noncross-linked NPs.
Gemcitabine entrapment efficiency & release profile
• The maximum entrapment efficiency of the system is around 42% for 1.6 mg/ml (above this concentration, the
system saturates).
• The system releases around 84% of the drug in the first 4 h.
Drug-loaded NPs cytotoxicity
• Drug-loaded NPs presented increased toxicity (around 25% at day 3) over human breast cancer cells when
compared with free gemcitabine.
• Drug-loaded NPs did not present increased toxicity over endothelial cells when compared with free gemcitabine.
• Drug-loaded NPs present higher toxicity over breast cancer cells (around 17%) when compared with endothelial
cells.
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